ANT-GROUP
22.10.2020 12:26:06 CEST | Business Wire | Press release
Ant Group, a leader in the development of open platforms for technology-driven inclusive financial services, and the parent company of China’s largest digital payment platform, Alipay, today unveiled its new digital copyright services platform powered by AntChain, the company’s blockchain-based technology. The platform aims to help millions of original creators verify and protect their copyright with greater efficiency and at a lower cost.
Powered by blockchain and AI technologies, the digital copyright services platform enables content creators to quickly authenticate and verify a variety of original works, from music scores to videos, images, and articles and essays. When a creator uploads his or her work onto the platform, the platform will first verify whether the content is the only one that exists within its database. It will then generate a unique digital copyright certification containing basic information about the work, as well as a notary stamp. These tamper-proof certifications can also be submitted as evidence in copyright infringement and tort cases.
The digital copyright services platform also provides identification and search services that can help creators effectively monitor and flag potential copyright infringement, making it easier and less costly for IP owners to verify and protect their original content.
Applying for copyright registration and certification is typically a complicated and time-consuming process. With the digital copyright services platform, this process is effectively shortened to one minute, and creators can save up to 95% in related expenditures.
"We believe that AntChain can play a pivotal role in building trust among multiple parties and solving real-life problems for the copyright industry," said Guofei Jiang, President of Advanced Technology Business Group, Ant Group. “The AntChain-powered digital copyright services platform was specifically designed to address the pain points that creators typically encounter when trying to authenticate and protect their work.”
Shanghai C.C. Music Culture Co Ltd, China's leading digital music score copyright distribution network, was one of the first partners to join the digital copyright services platform during its trial period. Now, musicians who are part of Shanghai C.C. Music Culture’s network can secure digital copyright certifications when they upload their original works to the platform. At the same time, AntChain will generate smart contracts that can record revenues generated by the musicians and the distributor. Once their work is successfully sold, the smart contract is triggered, and revenues will be automatically distributed to the musicians and Shanghai C.C. Music Culture.
Nianhua Yi, CEO of C.C. Music, commented, “The AntChain-powered digital copyright services platform enables the musicians on C.C. Music to register and certify their works with ease. That really brings great benefits for the creators.”
At present, more than 10 million original works are certified every day on the digital copyright services platform.
About AntChain
AntChain is Ant Group’s blockchain business. According to IPR Daily and patent database IncoPat, Ant Group held the highest number of published blockchain-related patent applications between 2017 and the six months ended June 30, 2020. Since the launch of Ant Group’s blockchain business in 2016, the company pioneered the use of AntChain in over 50 blockchain commercial applications and use cases, including supply chain finance, cross-border remittance, charitable donations and product provenance.
The AntChain platform consists of three layers including the underlying Blockchain-as-a-Service open platform, digitalization of assets, and circulation of digitalized assets. By enabling businesses to digitalize their assets and transactions, AntChain establishes trust in multi-party collaborations. The AntChain platform generated over 100 million daily active items such as patents, vouchers, and warehouse receipts, for the twelve months ended June 30, 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201022005573/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom